Bocquet et al.

RegiSCAR

J-SCAR^d

Cutaneous drug eruption^a

Y

Acute rash^b

Y

Maculopapular rash developing 3 weeks after starting offending drug

Y

Hematologic abnormalities^a

Reaction suspected to be drug-related^b

Y

Prolonged clinical symptoms after discontinuation of the causative drug

Y

Ÿ Eosinophils ≥ 1.5 × 10⁹/L

Y

Hospitalization^c

Y

Fever > 38˚C

Y

Ÿ Atypical lymphocytes

N

Fever > 38˚C

Y

Systemic involvement

Systemic involvement^a

Enlarged lymph nodes involving ≥ 2 sites^c

Y

Ÿ Liver abnormalities (ALT > 100 U/L) or other organ involvement

Y

Ÿ Lymph nodes ≥ 2 cm in diameter

Y

Involvement of ≥1 internal organ^c

Y

Ÿ Liver transaminases ≥ 2 times normal

Y

Blood count abnormalities^c

Leukocyte abnormalities (≥ 1)

Ÿ Interstitial nephritis

N

Ÿ Lymphocytes above or below normal limits

Y

Ÿ Leukocytosis (11 × 10⁹/L)

Y

Ÿ Interstitial pneumonitis

N

Ÿ Eosinophils over laboratory limits

Y

Ÿ Atypical lymphocytes (5%)

N

Ÿ Carditis

N

Ÿ Platelets under laboratory limits

N

Ÿ Eosinophils ≥ 1.5 × 10⁹/L

Y

Lymphadenopathy

Y

HHV-6 reactivation

N